schliessen

Filtern

 

Bibliotheken

Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin

The present investigation reports the preparation, optimization, and characterization of surface engineered solid lipid nanoparticles (SLNs) encapsulated with doxorubicin (DOX). Salient features such as biocompatibility, controlled release, target competency, potential of penetration, improved physi... Full description

Journal Title: Colloids and Surfaces B: Biointerfaces 01 October 2015, Vol.134, pp.47-58
Main Author: Jain, Ashay
Other Authors: Kesharwani, Prashant , Garg, Neeraj K , Jain, Atul , Jain, Som Akshay , Jain, Amit Kumar , Nirbhavane, Pradip , Ghanghoria, Raksha , Tyagi, Rajeev Kumar , Katare, Om Prakash
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0927-7765 ; E-ISSN: 1873-4367 ; DOI: 10.1016/j.colsurfb.2015.06.027
Link: https://www.sciencedirect.com/science/article/pii/S0927776515004002
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: elsevier_sdoi_10_1016_j_colsurfb_2015_06_027
title: Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin
format: Article
creator:
  • Jain, Ashay
  • Kesharwani, Prashant
  • Garg, Neeraj K
  • Jain, Atul
  • Jain, Som Akshay
  • Jain, Amit Kumar
  • Nirbhavane, Pradip
  • Ghanghoria, Raksha
  • Tyagi, Rajeev Kumar
  • Katare, Om Prakash
subjects:
  • Galactose
  • Solid Lipid Nanoparticles
  • Doxorubicin
  • Cytotoxicity
  • Lectin
  • Targeting
  • Engineering
  • Chemistry
  • Anatomy & Physiology
ispartof: Colloids and Surfaces B: Biointerfaces, 01 October 2015, Vol.134, pp.47-58
description: The present investigation reports the preparation, optimization, and characterization of surface engineered solid lipid nanoparticles (SLNs) encapsulated with doxorubicin (DOX). Salient features such as biocompatibility, controlled release, target competency, potential of penetration, improved physical stability, low cost and ease of scaling-up make SLNs viable alternative to liposomes for effective drug delivery. Galactosylation of SLNs instructs some gratifying characteristic, which leads to the evolution of promising delivery vehicles. The impendence of lectin receptors on different cell surfaces makes the galactosylated carriers admirable for targeted delivery of drugs to ameliorate their therapeutic index. Active participation of some lectin receptors in immune responses to antigen overlaid the application of galactosylated carriers in delivery of antigen and immunotherapy for treatment of maladies like cancer. These advantages revealed the promising potential of galactosylated carriers in each perspective of drug delivery. The developed DOX loaded galactosylated SLNs formulation was found to have particle size 239 ± 2.40 nm, PDI 0.307 ± 0.004, entrapment efficiency 72.3 ± 0.9%. Higher cellular uptake, cytotoxicity, and nuclear localization of galactosylated SLNs against A549 cells revealed higher efficiency of the formulation. In a nutshell, the galactosylation strategy with SLNs could be a promising approach in improving the delivery of DOX for cancer therapy.
language: eng
source:
identifier: ISSN: 0927-7765 ; E-ISSN: 1873-4367 ; DOI: 10.1016/j.colsurfb.2015.06.027
fulltext: fulltext
issn:
  • 0927-7765
  • 09277765
  • 1873-4367
  • 18734367
url: Link


@attributes
ID1528951798
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordiddoi_10_1016_j_colsurfb_2015_06_027
sourceidelsevier_s
recordidTN_elsevier_sdoi_10_1016_j_colsurfb_2015_06_027
sourcesystemOther
dbid
0--K
1--M
2.~1
31B1
41~.
5457
64G.
77-5
88P~
99JM
109JN
11AAEDT
12AAEPC
13AAKOC
14AAOAW
15AAQFI
16AARLI
17ABGSF
18ABNUV
19ABXRA
20ABYKQ
21ACDAQ
22ACFVG
23ACRLP
24ADECG
25ADEWK
26ADUVX
27AEHWI
28AEKER
29AEZYN
30AFKWA
31AFTJW
32AFXIZ
33AGHFR
34AGUBO
35AGYEJ
36AHPOS
37AIKHN
38AITUG
39AIVDX
40AJBFU
41AJOXV
42AJSZI
43AMFUW
44BLXMC
45DOVZS
46ENUVR
47EO8
48EO9
49EP2
50EP3
51FDB
52FIRID
53FLBIZ
54FNPLU
55G-Q
56GBLVA
57J1W
58KOM
59MAGPM
60OAUVE
61OGIMB
62P-8
63P-9
64PC.
65Q38
66RPZ
67SDF
68SDG
69SDP
70SES
71SPC
72SSG
73SSK
74SSM
75SSQ
76SSU
77SSZ
78T5K
79~G-
pqid1778005186
display
typearticle
titleGalactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin
creatorJain, Ashay ; Kesharwani, Prashant ; Garg, Neeraj K ; Jain, Atul ; Jain, Som Akshay ; Jain, Amit Kumar ; Nirbhavane, Pradip ; Ghanghoria, Raksha ; Tyagi, Rajeev Kumar ; Katare, Om Prakash
ispartofColloids and Surfaces B: Biointerfaces, 01 October 2015, Vol.134, pp.47-58
identifier
subjectGalactose ; Solid Lipid Nanoparticles ; Doxorubicin ; Cytotoxicity ; Lectin ; Targeting ; Engineering ; Chemistry ; Anatomy & Physiology
descriptionThe present investigation reports the preparation, optimization, and characterization of surface engineered solid lipid nanoparticles (SLNs) encapsulated with doxorubicin (DOX). Salient features such as biocompatibility, controlled release, target competency, potential of penetration, improved physical stability, low cost and ease of scaling-up make SLNs viable alternative to liposomes for effective drug delivery. Galactosylation of SLNs instructs some gratifying characteristic, which leads to the evolution of promising delivery vehicles. The impendence of lectin receptors on different cell surfaces makes the galactosylated carriers admirable for targeted delivery of drugs to ameliorate their therapeutic index. Active participation of some lectin receptors in immune responses to antigen overlaid the application of galactosylated carriers in delivery of antigen and immunotherapy for treatment of maladies like cancer. These advantages revealed the promising potential of galactosylated carriers in each perspective of drug delivery. The developed DOX loaded galactosylated SLNs formulation was found to have particle size 239 ± 2.40 nm, PDI 0.307 ± 0.004, entrapment efficiency 72.3 ± 0.9%. Higher cellular uptake, cytotoxicity, and nuclear localization of galactosylated SLNs against A549 cells revealed higher efficiency of the formulation. In a nutshell, the galactosylation strategy with SLNs could be a promising approach in improving the delivery of DOX for cancer therapy.
languageeng
source
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttps://www.sciencedirect.com/science/article/pii/S0927776515004002$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
search
creatorcontrib
0Jain, Ashay
1Kesharwani, Prashant
2Garg, Neeraj K
3Jain, Atul
4Jain, Som Akshay
5Jain, Amit Kumar
6Nirbhavane, Pradip
7Ghanghoria, Raksha
8Tyagi, Rajeev Kumar
9Katare, Om Prakash
titleGalactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin
description
subject
0Galactose
1Solid Lipid Nanoparticles
2Doxorubicin
3Cytotoxicity
4Lectin
5Targeting
6Engineering
7Chemistry
8Anatomy & Physiology
general
0English
1Elsevier B.V
210.1016/j.colsurfb.2015.06.027
3ScienceDirect (Elsevier B.V.)
4ScienceDirect Journals (Elsevier)
sourceidelsevier_s
recordidelsevier_sdoi_10_1016_j_colsurfb_2015_06_027
issn
00927-7765
109277765
21873-4367
318734367
rsrctypearticle
creationdate2015
addtitleColloids and Surfaces B: Biointerfaces
searchscope
0elsevier_full
1elsevier2
scope
0elsevier_full
1elsevier2
lsr44$$EView_record_in_ScienceDirect_(Access_to_full_text_may_be_restricted)
tmp01ScienceDirect Journals (Elsevier)
tmp02
0--K
1--M
2.~1
31B1
41~.
5457
64G.
77-5
88P~
99JM
109JN
11AAEDT
12AAEPC
13AAKOC
14AAOAW
15AAQFI
16AARLI
17ABGSF
18ABNUV
19ABXRA
20ABYKQ
21ACDAQ
22ACFVG
23ACRLP
24ADECG
25ADEWK
26ADUVX
27AEHWI
28AEKER
29AEZYN
30AFKWA
31AFTJW
32AFXIZ
33AGHFR
34AGUBO
35AGYEJ
36AHPOS
37AIKHN
38AITUG
39AIVDX
40AJBFU
41AJOXV
42AJSZI
43AMFUW
44BLXMC
45DOVZS
46ENUVR
47EO8
48EO9
49EP2
50EP3
51FDB
52FIRID
53FLBIZ
54FNPLU
55G-Q
56GBLVA
57J1W
58KOM
59MAGPM
60OAUVE
61OGIMB
62P-8
63P-9
64PC.
65Q38
66RPZ
67SDF
68SDG
69SDP
70SES
71SPC
72SSG
73SSK
74SSM
75SSQ
76SSU
77SSZ
78T5K
79~G-
startdate20151001
enddate20151001
lsr40Colloids and Surfaces B: Biointerfaces, 01 October 2015, Vol.134, pp.47-58
doi10.1016/j.colsurfb.2015.06.027
citationpf 47 pt 58 vol 134
lsr30VSR-Enriched:[orcidid, pqid]
sort
titleGalactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin
authorJain, Ashay ; Kesharwani, Prashant ; Garg, Neeraj K ; Jain, Atul ; Jain, Som Akshay ; Jain, Amit Kumar ; Nirbhavane, Pradip ; Ghanghoria, Raksha ; Tyagi, Rajeev Kumar ; Katare, Om Prakash
creationdate20151001
lso0120151001
facets
frbrgroupid8259346975164809417
frbrtype5
newrecords20190904
languageeng
topic
0Galactose
1Solid Lipid Nanoparticles
2Doxorubicin
3Cytotoxicity
4Lectin
5Targeting
6Engineering
7Chemistry
8Anatomy & Physiology
collectionScienceDirect (Elsevier B.V.)
prefilterarticles
rsrctypearticles
creatorcontrib
0Jain, Ashay
1Kesharwani, Prashant
2Garg, Neeraj K
3Jain, Atul
4Jain, Som Akshay
5Jain, Amit Kumar
6Nirbhavane, Pradip
7Ghanghoria, Raksha
8Tyagi, Rajeev Kumar
9Katare, Om Prakash
jtitleColloids and Surfaces B: Biointerfaces
creationdate2015
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Jain
1Kesharwani
2Garg
3Nirbhavane
4Ghanghoria
5Tyagi
6Katare
aufirst
0Ashay
1Prashant
2Neeraj K
3Atul
4Som Akshay
5Amit Kumar
6Pradip
7Raksha
8Rajeev Kumar
9Om Prakash
auinitA
auinit1A
au
0Jain, Ashay
1Kesharwani, Prashant
2Garg, Neeraj K
3Jain, Atul
4Jain, Som Akshay
5Jain, Amit Kumar
6Nirbhavane, Pradip
7Ghanghoria, Raksha
8Tyagi, Rajeev Kumar
9Katare, Om Prakash
atitleGalactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin
jtitleColloids and Surfaces B: Biointerfaces
risdate20151001
volume134
spage47
epage58
pages47-58
issn0927-7765
eissn1873-4367
formatjournal
genrearticle
ristypeJOUR
abstract
pubElsevier B.V
doi10.1016/j.colsurfb.2015.06.027
lad01Colloids and Surfaces B: Biointerfaces
orcidid0000-0002-0890-769X
date2015-10-01